Thomas Stankovich - ReShape Lifesciences Chief Officer
| RSLS Stock | USD 4.66 0.20 4.12% |
Executive
Thomas Stankovich is Chief Officer of ReShape Lifesciences
| Age | 64 |
| Address | 18 Technology Drive, Irvine, CA, United States, 92618 |
| Phone | 949-429-6680 |
| Web | https://www.reshapelifesciences.com |
Latest Insider Transactions
| 2023-10-25 | Disposed of 2 shares @ 15.66 | View | |
| 2023-10-11 | Disposed of shares @ 53.94 | ||
| 2023-09-01 | Disposed of 2 shares @ 51.62 | View | |
| 2023-08-24 | Disposed of shares @ 82.36 | ||
| 2023-08-04 | Disposed of 1 shares @ 82.94 | View | |
| 2023-07-06 | Disposed of 1 shares @ 85.26 | View | |
| 2023-06-30 | Acquired 305 shares @ 88.16 | View | |
| 2023-05-31 | Disposed of 1 shares @ 139.78 | View | |
| 2023-04-30 | Disposed of 1 shares @ 136.88 | View | |
| 2023-03-31 | Disposed of 1 shares @ 150.8 | View | |
| 2023-02-28 | Disposed of 1 shares @ 246.5 | View | |
| 2023-02-02 | Disposed of 2 shares @ 770.82 | View | |
| 2023-01-24 | Disposed of 2 shares @ 434.42 | View | |
| 2022-11-04 | Disposed of 2 shares @ 783 | View | |
| 2022-10-04 | Disposed of 2 shares @ 812 | View | |
| 2022-09-06 | Disposed of 1 shares @ 1131 | View | |
| 2022-08-05 | Disposed of 1 shares @ 1363 | View | |
| 2022-07-01 | Disposed of 1 shares @ 1595 | View |
Thomas Stankovich Latest Insider Activity
Tracking and analyzing the buying and selling activities of Thomas Stankovich against ReShape Lifesciences stock is an integral part of due diligence when investing in ReShape Lifesciences. Thomas Stankovich insider activity provides valuable insight into whether ReShape Lifesciences is net buyers or sellers over its current business cycle. Note, ReShape Lifesciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell ReShape Lifesciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Thomas Stankovich over three weeks ago Disposition of 109 shares by Thomas Stankovich of ReShape Lifesciences at 2.6 subject to Rule 16b-3 | ||
Thomas Stankovich over a month ago Disposition of tradable shares by Thomas Stankovich of ReShape Lifesciences at 7.49 subject to Rule 16b-3 | ||
Thomas Stankovich over a month ago Disposition of tradable shares by Thomas Stankovich of ReShape Lifesciences at 0.17 subject to Rule 16b-3 | ||
Thomas Stankovich over three months ago Disposition of tradable shares by Thomas Stankovich of ReShape Lifesciences at 0.25 subject to Rule 16b-3 |
ReShape Lifesciences Management Efficiency
The company has return on total asset (ROA) of (0.6346) % which means that it has lost $0.6346 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8459) %, meaning that it created substantial loss on money invested by shareholders. ReShape Lifesciences' management efficiency ratios could be used to measure how well ReShape Lifesciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.29 in 2025. Return On Capital Employed is likely to drop to -2.57 in 2025. At this time, ReShape Lifesciences' Total Current Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 4 M in 2025, whereas Other Assets are likely to drop slightly above 111.4 K in 2025.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Meshira Greenberg | Inspira Technologies Oxy | N/A | |
| Paul Wotta | Nuwellis | 68 | |
| Yafit Tehila | Inspira Technologies Oxy | 42 | |
| Lisa Wolf | Tivic Health Systems | 62 | |
| Vitaliy Epshteyn | Nuwellis | 46 | |
| Robert Scott | Nuwellis | 44 | |
| Kevin Williamson | Tenon Medical | 40 | |
| John Kowalczyk | Nuwellis | N/A | |
| Susan RN | NeuroMetrix | N/A | |
| FACC MD | Nuwellis | N/A | |
| Kimberly Bambach | Tivic Health Systems | 53 | |
| Deina Walsh | Bone Biologics Corp | 60 | |
| Michael Marcroft | SINTX Technologies | N/A | |
| Ryan Bock | SINTX Technologies | N/A | |
| Adi Nir | Inspira Technologies Oxy | N/A | |
| David OBrien | SINTX Technologies | 59 | |
| FACC MBA | Nuwellis | N/A | |
Management Performance
| Return On Equity | -1.85 | ||||
| Return On Asset | -0.63 |
ReShape Lifesciences Leadership Team
Elected by the shareholders, the ReShape Lifesciences' board of directors comprises two types of representatives: ReShape Lifesciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ReShape. The board's role is to monitor ReShape Lifesciences' management team and ensure that shareholders' interests are well served. ReShape Lifesciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ReShape Lifesciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Al Diaz, Vice RD | ||
| DVM DVM, VP Officer | ||
| Thomas Stankovich, Chief Officer | ||
| MBA DVM, VP Officer | ||
| Dan Gladney, Chairman of the Board and Presidentident, CEO | ||
| Jody Dahlman, Director Communications | ||
| Katherine Tweden, CoFounder | ||
| Paul Hickey, Senior Vice President - Marketing and Reimbursement | ||
| Mark Knudson, CoFounder CEO | ||
| Naqeeb Ansari, Senior Vice President - Sales |
ReShape Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ReShape Lifesciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.85 | ||||
| Return On Asset | -0.63 | ||||
| Profit Margin | (1.12) % | ||||
| Operating Margin | (1.05) % | ||||
| Current Valuation | 2.86 M | ||||
| Shares Outstanding | 712.68 K | ||||
| Shares Owned By Insiders | 5.57 % | ||||
| Shares Owned By Institutions | 1.83 % | ||||
| Number Of Shares Shorted | 18.45 K | ||||
| Price To Book | 2.29 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for ReShape Stock Analysis
When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.